Basis for molecular diagnostics and immunotherapy for esophageal cancer

Joe Abdo, Devendra K. Agrawal, Sumeet K. Mittal

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Introduction: Esophageal cancer (EC) is an extremely aggressive neoplasm, diagnosed in about 17,000 Americans every year with a mortality rate of more than 80% within five years and a median overall survival of just 13 months. For decades, the go-to regimen for esophageal cancer patients has been the use of taxane and platinum-based chemotherapy regimens, which has yielded the field’s most dire survival statistics. Areas covered: Combination immunotherapy and a more robust molecular diagnostic platform for esophageal tumors could improve patient management strategies and potentially extend lives beyond the current survival figures. Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC. Expert commentary: Of the 12 FDA-approved therapies in EC, zero target the genome. A majority of the approved drugs either target or are effected by proteomic expression. Therefore, a broader understanding of diagnostic biomarkers could give more clarity and direction in treating esophageal cancer in concert with a greater use of immunotherapy.

Original languageEnglish (US)
Pages (from-to)33-45
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume17
Issue number1
DOIs
StatePublished - Jan 2 2017

Fingerprint

Molecular Pathology
Esophageal Neoplasms
Immunotherapy
Platinum
Survival
Biomarkers
Proteomics
Neoplasms
Genome
Drug Therapy
Mortality
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Basis for molecular diagnostics and immunotherapy for esophageal cancer. / Abdo, Joe; Agrawal, Devendra K.; Mittal, Sumeet K.

In: Expert Review of Anticancer Therapy, Vol. 17, No. 1, 02.01.2017, p. 33-45.

Research output: Contribution to journalReview article

@article{1d855059fed54452a44584dfd6f1eb52,
title = "Basis for molecular diagnostics and immunotherapy for esophageal cancer",
abstract = "Introduction: Esophageal cancer (EC) is an extremely aggressive neoplasm, diagnosed in about 17,000 Americans every year with a mortality rate of more than 80{\%} within five years and a median overall survival of just 13 months. For decades, the go-to regimen for esophageal cancer patients has been the use of taxane and platinum-based chemotherapy regimens, which has yielded the field’s most dire survival statistics. Areas covered: Combination immunotherapy and a more robust molecular diagnostic platform for esophageal tumors could improve patient management strategies and potentially extend lives beyond the current survival figures. Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC. Expert commentary: Of the 12 FDA-approved therapies in EC, zero target the genome. A majority of the approved drugs either target or are effected by proteomic expression. Therefore, a broader understanding of diagnostic biomarkers could give more clarity and direction in treating esophageal cancer in concert with a greater use of immunotherapy.",
author = "Joe Abdo and Agrawal, {Devendra K.} and Mittal, {Sumeet K.}",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/14737140.2017.1260449",
language = "English (US)",
volume = "17",
pages = "33--45",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Basis for molecular diagnostics and immunotherapy for esophageal cancer

AU - Abdo, Joe

AU - Agrawal, Devendra K.

AU - Mittal, Sumeet K.

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Introduction: Esophageal cancer (EC) is an extremely aggressive neoplasm, diagnosed in about 17,000 Americans every year with a mortality rate of more than 80% within five years and a median overall survival of just 13 months. For decades, the go-to regimen for esophageal cancer patients has been the use of taxane and platinum-based chemotherapy regimens, which has yielded the field’s most dire survival statistics. Areas covered: Combination immunotherapy and a more robust molecular diagnostic platform for esophageal tumors could improve patient management strategies and potentially extend lives beyond the current survival figures. Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC. Expert commentary: Of the 12 FDA-approved therapies in EC, zero target the genome. A majority of the approved drugs either target or are effected by proteomic expression. Therefore, a broader understanding of diagnostic biomarkers could give more clarity and direction in treating esophageal cancer in concert with a greater use of immunotherapy.

AB - Introduction: Esophageal cancer (EC) is an extremely aggressive neoplasm, diagnosed in about 17,000 Americans every year with a mortality rate of more than 80% within five years and a median overall survival of just 13 months. For decades, the go-to regimen for esophageal cancer patients has been the use of taxane and platinum-based chemotherapy regimens, which has yielded the field’s most dire survival statistics. Areas covered: Combination immunotherapy and a more robust molecular diagnostic platform for esophageal tumors could improve patient management strategies and potentially extend lives beyond the current survival figures. Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC. Expert commentary: Of the 12 FDA-approved therapies in EC, zero target the genome. A majority of the approved drugs either target or are effected by proteomic expression. Therefore, a broader understanding of diagnostic biomarkers could give more clarity and direction in treating esophageal cancer in concert with a greater use of immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85006309044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006309044&partnerID=8YFLogxK

U2 - 10.1080/14737140.2017.1260449

DO - 10.1080/14737140.2017.1260449

M3 - Review article

VL - 17

SP - 33

EP - 45

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -